Academic Content and Language Evaluation of This Article
CrossCheck and Google Search of This Article
Academic Rules and Norms of This Article
Citation of this article
Corresponding Author of This Article
Research Domain of This Article
Article-Type of This Article
Open-Access Policy of This Article
Times Cited Counts in Google of This Article
Number of Hits and Downloads for This Article
- Total Article Views (6002)
All Articles published online
|
Publishing Process of This Article
|
Jul 20, 2022 (publication date) through Nov 5, 2024
Times Cited of This Article
Journal Information of This Article
Publication Name
World Journal of Methodology
ISSN
2222-0682
Publisher of This Article
Baishideng Publishing Group Inc, 7041 Koll Center Parkway, Suite 160, Pleasanton, CA 94566, USA
| For: | Kant R, Chandra L, Verma V, Nain P, Bello D, Patel S, Ala S, Chandra R, Antony MA. Gut microbiota interactions with anti-diabetic medications and pathogenesis of type 2 diabetes mellitus. World J Methodol 2022; 12(4): 246-257 [PMID: 36159100 DOI: 10.5662/wjm.v12.i4.246] |
|---|---|
| URL: | https://www.wjgnet.com/1949-8462/full/v12/i4/246.htm |
| Number | Citing Articles |
| 1 |
Nicoleta Mihaela Mindrescu, Cristian Guja, Viorel Jinga, Sorina Ispas, Antoanela Curici, Andreea Nelson Twakor, Anca Mihaela Pantea Stoian. Interactions between Gut Microbiota and Oral Antihyperglycemic Drugs: A Systematic Review. International Journal of Molecular Sciences 2024; 25(6): 3540 doi: 10.3390/ijms25063540
|
| 2 |
Samuel Oluwadare Olalekan, Olalekan Olanrewaju Bakare, Ifabunmi Oduyemi Osonuga, Abayomi Samson Faponle, Bukunola Oluyemisi Adegbesan, Esther Nkechi Ezima. Gut microbiota-derived metabolites: implications for metabolic syndrome and therapeutic interventions. The Egyptian Journal of Internal Medicine 2024; 36(1) doi: 10.1186/s43162-024-00342-4
|
| 3 |
Mc Anto Antony, Aniqa Chowdhury, Dinesh Edem, Rishi Raj, Priyanshu Nain, Mansi Joglekar, Vipin Verma, Ravi Kant. Gut microbiome supplementation as therapy for metabolic syndrome. World Journal of Diabetes 2023; 14(10): 1502-1513 doi: 10.4239/wjd.v14.i10.1502
Abstract(554) |
Core Tip(529) |
Full Article(HTML)(3145)
|
Full Article with Cover (PDF)-1622K(107)
|
Full Article (Word)-18469K(43)
|
Audio-835K(3)
|
Peer-Review Report-229K(58)
|
Answering Reviewers-175K(65)
|
Full Article (PDF)-1315K(230)
|
Full Article (XML)-176K(55)
|
Times Cited (10)
|
Total Visits (6025)
|
Open
|
| 4 |
Antonino Colloca, Isabella Donisi, Camilla Anastasio, Maria Luisa Balestrieri, Nunzia D’Onofrio. Metabolic Alteration Bridging the Prediabetic State and Colorectal Cancer. Cells 2024; 13(8): 663 doi: 10.3390/cells13080663
|
| 5 |
Margit Wunderlich, Manuel Miller, Bärbel Ritter, Ronan Le Gleut, Hannah Marchi, Monir Majzoub-Altweck, Patrick J. Knerr, Jonathan D. Douros, Timo D. Müller, Markus Brielmeier. Experimental colonization with H. hepaticus, S. aureus and R. pneumotropicus does not influence the metabolic response to high-fat diet or incretin-analogues in wildtype SOPF mice. Molecular Metabolism 2024; 87: 101992 doi: 10.1016/j.molmet.2024.101992
|
| 6 |
Jane Shearer, Shrushti Shah, Grace Shen-Tu, Kristina Schlicht, Matthias Laudes, Chunlong Mu. Microbial Features Linked to Medication Strategies in Cardiometabolic Disease Management. ACS Pharmacology & Translational Science 2024; 7(4): 991 doi: 10.1021/acsptsci.3c00261
|
| 7 |
Khaled Naja, Najeha Anwardeen, Sara S. Bashraheel, Mohamed A. Elrayess. Pharmacometabolomics of sulfonylureas in patients with type 2 diabetes: a cross-sectional study. Journal of Pharmacy & Pharmaceutical Sciences 2024; 27 doi: 10.3389/jpps.2024.13305
|
| 8 |
Omar M. Makram, Priyanshu Nain, Alexi Vasbinder, Neal L. Weintraub, Avirup Guha. Cardiovascular Risk Assessment and Prevention in Cardio-Oncology. Cardiology Clinics 2024; doi: 10.1016/j.ccl.2024.08.003
|
| 9 |
Bin Yao, Baochao Pan, Tian Tian, Xiuhai Su, Shufang Zhang, Hanzhou Li, Wendong Li, Yuansong Wang, Shuquan Lv, Zhaiyi Zhang. Baihu renshen decoction ameliorates type 2 diabetes mellitus in rats through affecting gut microbiota enhancing gut permeability and inhibiting TLR4/NF-κB-mediated inflammatory response. Frontiers in Cellular and Infection Microbiology 2022; 12 doi: 10.3389/fcimb.2022.1051962
|
| 10 |
Berrak Erkan, Dilan Tekuzman, Sena Bade Kolukısa, Julide Sedef Göçmen. BAĞIRSAK MİKROBİYOTASININ KARDİYOVASKÜLER, ENDOKRİN VE NÖROLOJİK SİSTEMLER ÜZERİNDEKİ ETKİLERİ. Kırıkkale Üniversitesi Tıp Fakültesi Dergisi 2024; 26(1): 100 doi: 10.24938/kutfd.1401207
|
| 11 |
Yong-Wei Xu, Jun Tian, Yan Song, Ba-Cui Zhang, Jing Wang. Metabolic syndrome’s new therapy: Supplement the gut microbiome. World Journal of Diabetes 2024; 15(4): 793-796 doi: 10.4239/wjd.v15.i4.793
|
| 12 |
Nima Zafari, Mahla Velayati, Shima Mehrabadi, Sedigheh Damavandi, Majid Khazaei, Seyed Mahdi Hassanian, Gordon A. Ferns, Amir Avan. Remodeling of the Gut Microbiota in Colorectal Cancer and its Association
with Obesity. Current Pharmaceutical Design 2023; 29(4): 256 doi: 10.2174/1381612829666230118123018
|
| 13 |
Meyammai Shanmugham, Sophie Bellanger, Chen Huei Leo. Gut-Derived Metabolite, Trimethylamine-N-oxide (TMAO) in Cardio-Metabolic Diseases: Detection, Mechanism, and Potential Therapeutics. Pharmaceuticals 2023; 16(4): 504 doi: 10.3390/ph16040504
|